The intrarterial radioembolization of primary neoplasms and liver metastases is correct

Radioembolization, also known as selective internal radiation therapy (SIRT), is a minimally invasive therapy that has shown remarkable success in the treatment of primary and . This procedure involves delivering radioactive microspheres directly into the arteries supplying the tumors, resulting in targeted radiation therapy to destroy the tumor cells.

The use of intrarterial radioembolization has gained traction in recent years due to its effectiveness and reduced side effects compared to traditional therapies. This procedure provides a local and controlled delivery of radiation, sparing healthy tissues and reducing the risk of systemic side effects.

One of the primary benefits of intrarterial radioembolization is its ability to treat both primary liver cancer, such as hepatocellular carcinoma (HCC), and liver metastases from various other cancers. In patients with primary liver cancer who are not amenable to surgery or other local treatments, radioembolization has emerged as a promising alternative. It can be used as a standalone treatment or in conjunction with other therapies, such as chemotherapy or targeted agents.

For patients with liver metastases, intrarterial radioembolization offers a valuable treatment option. It can be used when surgical resection is not feasible or may result in insufficient tumor clearance. Metastatic tumors often pose a challenge due to their multiplicity and location, making traditional treatments less effective. Radioembolization provides a localized radiation therapy that targets the tumors directly, resulting in improved and quality of life for these patients.

Multiple clinical studies and real-world evidence have demonstrated the efficacy and safety of intrarterial radioembolization in primary neoplasms and liver metastases. A systematic review of 40 studies involving over 3,000 patients with HCC showed an overall response rate of 51.2% and a median survival of 12.5 months. Similar results have been observed in patients with liver metastases, indicating the potential of radioembolization as a viable treatment option for these conditions.

Furthermore, studies have shown that intrarterial radioembolization has a favorable safety profile and is well-tolerated by patients. The most common adverse events reported include mild fatigue, nausea, and abdominal pain, which are generally manageable and transient. The procedure itself is minimally invasive, with a low risk of complications when performed by experienced interventional radiologists.

Additionally, as radioembolization is a locoregional therapy, it can be repeated if necessary, allowing for continuous tumor control. This flexibility is especially beneficial in cases where multiple treatments are required due to tumor recurrence or progression.

In conclusion, the intrarterial radioembolization of primary neoplasms and liver metastases is a correct and effective treatment option. It offers targeted radiation therapy directly to the tumor site, resulting in improved outcomes and reduced side effects compared to traditional treatments. With its proven efficacy and safety, radioembolization is becoming an increasingly important tool in the multidisciplinary approach to liver cancer and metastases. As research and technology continue to advance, this innovative therapy holds great promise for the future of cancer treatment.